BioPharma Resources

Drug Trial Radar · NCT04854668

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 748 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

748

Actual

Start

May 27, 2021

Primary completion

Dec 31, 2024

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of 1:1. This study is conducted to assess the efficacy and safety of Anlotinib and Chemotherapy as first-line treatment in subjects with RAS/BRAF wild-type Metastatic Colorectal Cancer.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Anlotinib hydrochloride capsuleDrug

    Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21);

  • BevacizumabDrug

    Bevacizumab 7.5mg/kg, intravenous drip, on Day 1

  • OxaliplatinDrug

    Oxaliplatin 130mg/m2, intravenous drip, on Day 1;

  • CapecitabineDrug

    Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) assessed by IRCTime frame: Baseline up to 15 months

Locations

92 sites in 1 country. Site status is shown where the registry gives one.

  • The People's Hospital of Chizhou

    Chizhou, Anhui, China

  • Fujian Medical University Union Hospital

    Fuzhou, Anhui, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Anhui Cancer Hospital

    Hefei, Anhui, China

  • Xuancheng People's Hospital

    Xuancheng, Anhui, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University Frist Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fuling Hospital Affiliated to Chongqing University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • The First Affiliated Hospital Of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Qingyuan People's Hospital

    Qingyuan, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Liuzhou Workers' Hospital

    Liuzhou, Guangxi, China

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • The First Hospital of Qinhuangdao

    Qinhuangdao, Hebei, China

  • Tangshan People's Hospital

    Tangshan, Hebei, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Huaihe Hospital of Henan University

    Kaifeng, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Nanyang Second General Hospital

    Nanyang, Henan, China

  • Xinyang Central Hospital

    Xinyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of ZhengZhou University

    Zhengzhou, Henan, China

  • Tongji Hospital Affiliated to Tongji Medical College Hust

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Affiliated Hospital of Chifeng University

    Chifeng, Inner Mongolia, China

  • Chifeng Municipal hospital

    Chifeng, Inner Mongolia, China

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.